Replimune (REPL) Treasury Shares (2018)
Replimune (REPL) posted Treasury Shares of $5.5 million for Q1 2026, down 2.72% sequentially from $5.7 million in Q4 2025, and up 52.53% YoY from $3.6 million in Q1 2025.
Analysis
Replimune (REPL) Treasury Shares (2018) Analysis & Trends
Replimune has reported Treasury Shares for 7 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Treasury Shares rose 52.53% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 52.53% YoY) and the FY2026 annual result came in at $5.5 million, up 52.53% from the prior year.
- Treasury Shares declined to $5.5 million in Q1 2026 per REPL's latest filing, from $5.7 million in the prior quarter.
- Over five years, Treasury Shares peaked at $5.7 million in Q4 2025 and troughed at $826213.0 in Q1 2022.
- A 5-year average of $3.0 million and a median of $2.4 million in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares jumped 5071.91% in 2022, then soared 46.07% in 2025.
- Over 5 years, Treasury Shares stood at $1.4 million in 2022, then surged by 50.77% to $2.0 million in 2023, then soared by 71.06% to $3.5 million in 2024, then surged by 62.2% to $5.7 million in 2025, then declined by 2.72% to $5.5 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $5.5 million, $5.7 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 1.93 Mn |
| Jun 30, 2018 | 1.93 Mn |
| Mar 31, 2018 | 1.93 Mn |
| Mar 31, 2018 | 1.93 Mn |